Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity

Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity

Oral atorvastatin has prevented or reversed paralysis in the multiple sclerosis (MS) model experimental autoimmune encephalomyelitis (EAE), and reduced development of new MS lesions in clinical trials. Besides inhibiting development of encephalitogenic T cells, atorvastatin treatment of EAE has been...

Full description

Bibliographic Details
Main Authors: Weber, Martin S, Prod’homme, Thomas, Youssef, Sawsan, Dunn, Shannon E, Steinman, Lawrence, Zamvil, Scott S
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922392/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922392/

Similar Items